Principal Financial Group Inc I Teos Therapeutics, Inc. Transaction History

Principal Financial Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$8.57 - $11.06 $1.16 Million - $1.5 Million	-135,912 Reduced 89.22%	16,430 $179,000
Q3 2023 Nov 02, 2023	BUY	$10.95 - $14.6 $60,827 - $81,103	5,555 Added 3.78%	152,342 $1.67 Million
Q2 2023 Aug 07, 2023	SELL	$12.93 - $18.05 $108,224 - $151,078	-8,370 Reduced 5.39%	146,787 $1.94 Million
Q1 2023 May 09, 2023	SELL	$13.02 - $22.62 $43,369 - $75,347	-3,331 Reduced 2.1%	155,157 $2.11 Million
Q4 2022 Feb 09, 2023	SELL	$17.77 - $21.6 $189,445 - $230,277	-10,661 Reduced 6.3%	158,488 $3.1 Million
Q3 2022 Nov 09, 2022	BUY	$18.6 - $27.25 $26,021 - $38,122	1,399 Added 0.83%	169,149 $3.22 Million
Q2 2022 Aug 10, 2022	BUY	$16.57 - $35.1 $513,736 - $1.09 Million	31,004 Added 22.67%	167,750 $3.46 Million
Q1 2022 May 09, 2022	BUY	$31.92 - $47.45 $4.36 Million - $6.49 Million	136,746 New	136,746 $4.4 Million
Q3 2021 Nov 09, 2021	SELL	$23.91 - $29.58 $193,431 - $239,302	-8,090 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$17.9 - $36.1 $144,811 - $292,049	8,090 New	8,090 $0

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.